83_FR_7234 83 FR 7200 - National Institute on Drug Abuse; Notice of Closed Meetings

83 FR 7200 - National Institute on Drug Abuse; Notice of Closed Meetings

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 83, Issue 34 (February 20, 2018)

Page Range7200-7201
FR Document2018-03324

Federal Register, Volume 83 Issue 34 (Tuesday, February 20, 2018) 
[Federal Register Volume 83, Number 34 (Tuesday, February 20, 2018)]
[Notices]
[Pages 7200-7201]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2018-03324]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Exploiting HIV and/or Host Genomic Information to 
Understand HIV Compartments or Reactivation in Individuals with 
Substance Use Disorders (R61/R33).
    Date: March 7, 2018.
    Time: 11:00 a.m. to 2:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Hilton Garden Inn Bethesda, 7301 Waverly Street, 
Bethesda, MD 20814.


[[Page 7201]]


    Contact Person: Ivan K. Navarro, Ph.D., Scientific Review 
Officer, Office of Extramural Policy and Review, Division of 
Extramural Research, National Institute on Drug Abuse, NIH, DHHS, 
6001 Executive Boulevard, Room 4242, MSC 9550, Bethesda, MD 20892, 
301-827-5833, [email protected].

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Identification of Genetic and Genomic Variants by 
Next-Gen Sequencing in Non-Human Animal Models (U01).
    Date: March 7, 2018.
    Time: 1:00 p.m. to 4:00 p.m.
    Agenda: To review and evaluate cooperative agreement 
applications.
    Place: National Institutes of Health, Neuroscience Center, 6001 
Executive Boulevard, Rockville, MD 20852 (Telephone Conference 
Call).
    Contact Person: Gerald L. McLaughlin, Ph.D., Scientific Review 
Officer, Office of Extramural Policy and Review, National Institute 
on Drug Abuse, NIH, DHHS, 6001 Executive Blvd., Room 4238, MSC 9550, 
Bethesda, MD 20892-9550, 301-827-5819, [email protected].

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; NIDA Research ``Center of Excellence'' Grant Program 
(P50).
    Date: March 13-15, 2018.
    Time: 9:00 a.m. to 12:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Courtyard by Marriott Chevy Chase, 5520 Wisconsin Avenue, 
Chevy Chase, MD 20815.
    Contact Person: Gerald L. McLaughlin, Ph.D., Scientific Review 
Officer, Office of Extramural Policy and Review, National Institute 
on Drug Abuse, NIH, DHHS, 6001 Executive Blvd., Room 4238, MSC 9550, 
Bethesda, MD 20892-9550, 301-827-5819, [email protected].

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; NIDA Core Center of Excellence Grant Program (P30).
    Date: March 15, 2018.
    Time: 9:00 a.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Courtyard by Marriott Chevy Chase, 5520 Wisconsin Avenue, 
Chevy Chase, MD 20815.
    Contact Person: Gerald L. McLaughlin, Ph.D., Scientific Review 
Officer, Office of Extramural Policy and Review, National Institute 
on Drug Abuse, NIH, DHHS, 6001 Executive Blvd., Room 4238, MSC 9550, 
Bethesda, MD 20892-9550, 301-827-5819, [email protected].

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Phase II: Avenir Award Program for Research on 
Substance Abuse and HIV/AIDS (DP2).
    Date: March 19, 2018.
    Time: 8:00 a.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Courtyard by Marriott Chevy Chase, 5520 Wisconsin Avenue, 
Chevy Chase, MD 20815.
    Contact Person: Hiromi Ono, Ph.D., Scientific Review Officer, 
Office of Extramural Policy and Review, National Institute on Drug 
Abuse, National Institutes of Health, DHHS, 6001 Executive 
Boulevard, Room 4238, MSC 9550, Bethesda, MD 20892, 301-827-5820, 
[email protected].

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Phase II: Avenir Award Program for Genetics or 
Epigenetics of Substance Use Disorders (DP1).
    Date: March 21, 2018.
    Time: 9:00 a.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 
Wisconsin Avenue, Bethesda, MD 20814.
    Contact Person: Ivan K. Navarro, Ph.D., Scientific Review 
Officer, Office of Extramural Policy and Review, Division of 
Extramural Research, National Institute on Drug Abuse, NIH, DHHS, 
6001 Executive Boulevard, Room 4242, MSC 9550, Bethesda, MD 20892, 
301-827-5833, [email protected].

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Multi-Site Studies for System-Level Implementation 
of Substance Use Prevention and Treatment Services (R01; R34).
    Date: March 23, 2018.
    Time: 11:00 a.m. to 2:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Neuroscience Center, 6001 
Executive Boulevard, Rockville, MD 20852 (Telephone Conference 
Call).
    Contact Person: Julia Berzhanskaya, Ph.D., Scientific Review 
Officer, Office of Extramural Policy and Review, Division of 
Extramural Research, National Institute on Drug Abuse, NIH, DHHS, 
6001 Executive Boulevard, Room 4234, MSC 9550, Bethesda, MD 20892, 
301-827-5840, [email protected].

(Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug 
Abuse and Addiction Research Programs, National Institutes of 
Health, HHS)

    Dated: February 13, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2018-03324 Filed 2-16-18; 8:45 am]
 BILLING CODE 4140-01-P

7200 Federal Register / Vol. 83, No. 34 / Tuesday, February 20, 2018 / Notices Agenda: To review and evaluate grant Name of Committee: Center for Scientific Contact Person: Soheyla Saadi, Ph.D., applications. Review Special Emphasis Panel; Electronic Scientific Review Officer, Center for Place: National Institutes of Health, 6701 Nicotine Delivery Systems: Basic Scientific Review, National Institutes of Rockledge Drive, Bethesda, MD 20892, Mechanisms of Health Effects—PAR Panel. Health, 6701 Rockledge Drive, Room 3211, (Virtual Meeting). Date: March 15–16, 2018. MSC 7808, Bethesda, MD 20892, 301–435– Contact Person: Songtao Liu, MD, Time: 9:00 a.m. to 5:00 p.m. 0903, saadisoh@csr.nih.gov. Scientific Review Officer, Center for Agenda: To review and evaluate grant Name of Committee: Center for Scientific Scientific Review, National Institutes of applications. Review Special Emphasis Panel; Zika Virus Health, 6701 Rockledge Drive, Room 5118, Place: National Institutes of Health, 6701 Complications. Bethesda, MD 20817, 301–827–6828, Rockledge Drive, Bethesda, MD 20892, Date: March 16, 2018. songtao.liu@nih.gov. (Virtual Meeting). Time: 10:00 a.m. to 6:00 p.m. Name of Committee: Center for Scientific Contact Person: Ghenima Dirami, Ph.D., Agenda: To review and evaluate grant Review Special Emphasis Panel Small Scientific Review Officer, Center for applications. Business: Instrumentation, Environmental, Scientific Review, National Institutes of Place: National Institutes of Health, 6701 and Occupational Safety. Health, 6701 Rockledge Drive, Room 4122, Rockledge Drive, Bethesda, MD 20892. Date: March 12–13, 2018. MSC 7814, Bethesda, MD 20892, 240–498– Contact Person: John C. Pugh, Ph.D., Time: 8:00 a.m. to 12:00 p.m. 7546, diramig@csr.nih.gov. Scientific Review Officer, Center for Agenda: To review and evaluate grant Name of Committee: Center for Scientific Scientific Review, National Institutes of applications. Review Special Emphasis Panel; PAR17–158: Health, 6701 Rockledge Drive, Room 3114, Place: Hotel Nikko San Francisco, 222 Psychopathology and Neuronal Networks. MSC 7808, Bethesda, MD 20892, (301) 435– Mason Street, San Francisco, CA 94102. Date: March 15, 2018. 2398, pughjohn@csr.nih.gov. Contact Person: Marie-Jose Belanger, Ph.D., Time: 3:00 p.m. to 6:00 p.m. (Catalogue of Federal Domestic Assistance Scientific Review Officer, Center for Agenda: To review and evaluate grant Program Nos. 93.306, Comparative Medicine; Scientific Review, National Institutes of applications. 93.333, Clinical Research, 93.306, 93.333, Health, 6701 Rockledge Drive, Rm 6188 MSC Place: National Institutes of Health, 6701 93.337, 93.393–93.396, 93.837–93.844, 7804, Bethesda, MD 20892, 301–435–1267, Rockledge Drive, Bethesda, MD 20892, 93.846–93.878, 93.892, 93.893, National belangerm@csr.nih.gov. (Telephone Conference Call). Institutes of Health, HHS) Name of Committee: Center for Scientific Contact Person: Julius Cinque, MS, Scientific Review Officer, Center for Dated: February 13, 2018. Review Special Emphasis Panel Small Business: Psycho/Neuropathology Lifespan Scientific Review, National Institutes of Natasha M. Copeland, Development, STEM Education. Health, 6701 Rockledge Drive, Room 5186, Program Analyst, Office of Federal Advisory Date: March 15–16, 2018. MSC 7846, Bethesda, MD 20892, (301) 435– Committee Policy. Time: 8:00 a.m. to 6:00 p.m. 1252, cinquej@csr.nih.gov. [FR Doc. 2018–03321 Filed 2–16–18; 8:45 am] Agenda: To review and evaluate grant Name of Committee: AIDS and Related BILLING CODE 4140–01–P applications. Research Integrated Review Group AIDS Place: Hyatt Centric Arlington, 1325 Immunology and Pathogenesis Study Wilson Boulevard, Arlington, VA 22209. Section. DEPARTMENT OF HEALTH AND Contact Person: Elia E. Femia, Ph.D., Date: March 16, 2018. Scientific Review Officer, Center for Time: 8:00 a.m. to 5:00 p.m. HUMAN SERVICES Scientific Review, National Institutes of Agenda: To review and evaluate grant Health, 6701 Rockledge Drive Room 3108, applications. National Institutes of Health Bethesda, md 20892, 301–827–7189, Place: The Fairmont Washington, DC, 2401 femiaee@csr.nih.gov. M Street NW, Washington, DC 20037. National Institute on Drug Abuse; Contact Person: Shiv A. Prasad, Ph.D., Notice of Closed Meetings Name of Committee: Center for Scientific Review Special Emphasis Panel Small Scientific Review Officer, Center for Pursuant to section 10(d) of the Business: Medical Imaging. Scientific Review, National Institutes of Federal Advisory Committee Act, as Date: March 15–16, 2018. Health, 6701 Rockledge Drive, Room 5220, MSC 7852, Bethesda, MD 20892, 301–443– amended, notice is hereby given of the Time: 8:00 a.m. to 5:00 p.m. following meetings. Agenda: To review and evaluate grant 5779, prasads@csr.nih.gov. The meetings will be closed to the applications. Name of Committee: Center for Scientific Place: The Westgate Hotel, 1055 Second Review Special Emphasis Panel; Member public in accordance with the Avenue, San Diego, CA 92101. Conflict: Language and Communication. provisions set forth in sections Contact Person: Leonid V. Tsap, Ph.D., Date: March 16, 2018. 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Scientific Review Officer, Center for Time: 10:00 a.m. to 1:00 p.m. as amended. The grant applications and Scientific Review, National Institutes of Agenda: To review and evaluate grant the discussions could disclose Health, 6701 Rockledge Drive, Room 5128, applications. confidential trade secrets or commercial MSC 7854, Bethesda, MD 20892, (301) 435– Place: National Institutes of Health, 6701 property such as patentable material, 2507, tsapl@csr.nih.gov. Rockledge Drive, Bethesda, MD 20892, and personal information concerning Name of Committee: Center for Scientific (Telephone Conference Call). individuals associated with the grant Review Special Emphasis Panel Small Contact Person: Serena Chu, Ph.D., Scientific Review Officer, BBBP IRG, Center applications, the disclosure of which Business: Clinical Neurophysiology, Devices, for Scientific Review, National Institutes of would constitute a clearly unwarranted Neuroprosthetics, and Biosensors. Date: March 15–16, 2018. Health, 6701 Rockledge Drive, Room 3178, invasion of personal privacy. Time: 8:00 a.m. to 5:00 p.m. MSC 7848, Bethesda, MD 20892, 301–500– Name of Committee: National Institute on Agenda: To review and evaluate grant 5829, sechu@csr.nih.gov. Drug Abuse Special Emphasis Panel; applications. Name of Committee: Center for Scientific Exploiting HIV and/or Host Genomic Place: Residence Inn Washington, DC Review Special Emphasis Panel; Member Information to Understand HIV sradovich on DSK3GMQ082PROD with NOTICES Downtown, 1199 Vermont Ave. NW, Conflict: Topics in Bacterial Pathogenesis Compartments or Reactivation in Individuals Washington, DC 20005. and Host Interactions. with Substance Use Disorders (R61/R33). Contact Person: Cristina Backman, Ph.D., Date: March 16, 2018. Date: March 7, 2018. Scientific Review Officer, ETTN IRG, Center Time: 10:00 a.m. to 6:00 p.m. Time: 11:00 a.m. to 2:00 p.m. for Scientific Review, National Institutes of Agenda: To review and evaluate grant Agenda: To review and evaluate grant Health, 6701 Rockledge Drive, Room 5211, applications. applications. MSC 7846, Bethesda, MD 20892, 301–480– Place: National Institutes of Health, 6701 Place: Hilton Garden Inn Bethesda, 7301 9069, cbackman@mail.nih.gov. Rockledge Drive, Bethesda, MD 20892. Waverly Street, Bethesda, MD 20814. VerDate Sep<11>2014 17:55 Feb 16, 2018 Jkt 244001 PO 00000 Frm 00065 Fmt 4703 Sfmt 4703 E:\FR\FM\20FEN1.SGM 20FEN1

Federal Register / Vol. 83, No. 34 / Tuesday, February 20, 2018 / Notices 7201 Contact Person: Ivan K. Navarro, Ph.D., Contact Person: Hiromi Ono, Ph.D., provisions set forth in sections Scientific Review Officer, Office of Scientific Review Officer, Office of 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Extramural Policy and Review, Division of Extramural Policy and Review, National as amended. The grant applications Extramural Research, National Institute on Institute on Drug Abuse, National Institutes Drug Abuse, NIH, DHHS, 6001 Executive of Health, DHHS, 6001 Executive Boulevard, and/or contract proposals and the Boulevard, Room 4242, MSC 9550, Bethesda, Room 4238, MSC 9550, Bethesda, MD 20892, discussions could disclose confidential MD 20892, 301–827–5833, ivan.navarro@ 301–827–5820, hiromi.ono@nih.gov. trade secrets or commercial property nih.gov. Name of Committee: National Institute on such as patentable material, and Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Phase personal information concerning Drug Abuse Special Emphasis Panel; II: Avenir Award Program for Genetics or individuals associated with grant Identification of Genetic and Genomic Epigenetics of Substance Use Disorders (DP1). applications and/or contract proposals, Variants by Next-Gen Sequencing in Non- Human Animal Models (U01). Date: March 21, 2018. the disclosure of which would Date: March 7, 2018. Time: 9:00 a.m. to 5:00 p.m. constitute a clearly unwarranted Time: 1:00 p.m. to 4:00 p.m. Agenda: To review and evaluate grant invasion of personal privacy. Agenda: To review and evaluate applications. Place: Hyatt Regency Bethesda, One Name of Committee: National Cancer cooperative agreement applications. Bethesda Metro Center, 7400 Wisconsin Institute Special Emphasis Panel; Targeted Place: National Institutes of Health, Neuroscience Center, 6001 Executive Avenue, Bethesda, MD 20814. Radiotherapy & Radiation-Induced Toxicity. Boulevard, Rockville, MD 20852 (Telephone Contact Person: Ivan K. Navarro, Ph.D., Date: March 20, 2018. Conference Call). Scientific Review Officer, Office of Time: 12:00 p.m. to 4:00 p.m. Contact Person: Gerald L. McLaughlin, Extramural Policy and Review, Division of Agenda: To review and evaluate contract Ph.D., Scientific Review Officer, Office of Extramural Research, National Institute on proposals. Extramural Policy and Review, National Drug Abuse, NIH, DHHS, 6001 Executive Place: National Cancer Institute, Shady Institute on Drug Abuse, NIH, DHHS, 6001 Boulevard, Room 4242, MSC 9550, Bethesda, Grove, 9609 Medical Center Drive, Room Executive Blvd., Room 4238, MSC 9550, MD 20892, 301–827–5833, ivan.navarro@ 3W034, Rockville, MD 20850 (Telephone Bethesda, MD 20892–9550, 301–827–5819, nih.gov. Conference Call). gm145a@nih.gov. Name of Committee: National Institute on Contact Person: Ivan Ding, Ph.D., Scientific Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Multi- Site Studies for System-Level Review Officer, Program & Review Drug Abuse Special Emphasis Panel; NIDA Extramural Staff Training Office, Division of Research ‘‘Center of Excellence’’ Grant Implementation of Substance Use Prevention and Treatment Services (R01; R34). Extramural Activities, National Cancer Program (P50). Date: March 23, 2018. Institute, NIH, 9609 Medical Center Drive, Date: March 13–15, 2018. Time: 9:00 a.m. to 12:00 p.m. Time: 11:00 a.m. to 2:00 p.m. Room 7W236, Bethesda, MD 20892–9750, Agenda: To review and evaluate grant Agenda: To review and evaluate grant 240–276–6444, dingi@mail.nih.gov. applications. applications. Name of Committee: National Cancer Place: Courtyard by Marriott Chevy Chase, Place: National Institutes of Health, Institute Special Emphasis Panel; R13 5520 Wisconsin Avenue, Chevy Chase, MD Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Telephone Conference Grant Review. 20815. Date: March 20, 2018. Contact Person: Gerald L. McLaughlin, Conference Call). Contact Person: Julia Berzhanskaya, Ph.D., Time: 12:00 p.m. to 5:00 p.m. Ph.D., Scientific Review Officer, Office of Scientific Review Officer, Office of Agenda: To review and evaluate grant Extramural Policy and Review, National Extramural Policy and Review, Division of applications. Institute on Drug Abuse, NIH, DHHS, 6001 Extramural Research, National Institute on Place: National Cancer Institute, Shady Executive Blvd., Room 4238, MSC 9550, Drug Abuse, NIH, DHHS, 6001 Executive Grove, 9609 Medical Center Drive, Room Bethesda, MD 20892–9550, 301–827–5819, Boulevard, Room 4234, MSC 9550, Bethesda, 7W556, Rockville, MD 20850 (Telephone gm145a@nih.gov. MD 20892, 301–827–5840, Conference Call). Name of Committee: National Institute on julia.berzhanskaya@nih.gov. Drug Abuse Special Emphasis Panel; NIDA Contact Person: Bratin K. Saha, Ph.D., (Catalogue of Federal Domestic Assistance Scientific Review Officer, Program Core Center of Excellence Grant Program Program Nos.: 93.279, Drug Abuse and (P30). Coordination and Referral Branch, Division Addiction Research Programs, National Date: March 15, 2018. Institutes of Health, HHS) of Extramural Activities, National Cancer Time: 9:00 a.m. to 5:00 p.m. Institute, NIH, 9609 Medical Center Drive, Agenda: To review and evaluate grant Dated: February 13, 2018. Room 7W556, Bethesda, MD 20892–9750, applications. Natasha M. Copeland, 240–276–6411. Place: Courtyard by Marriott Chevy Chase, Program Analyst, Office of Federal Advisory 5520 Wisconsin Avenue, Chevy Chase, MD (Catalogue of Federal Domestic Assistance Committee Policy. Program Nos. 93.392, Cancer Construction; 20815. [FR Doc. 2018–03324 Filed 2–16–18; 8:45 am] 93.393, Cancer Cause and Prevention Contact Person: Gerald L. McLaughlin, Ph.D., Scientific Review Officer, Office of BILLING CODE 4140–01–P Research; 93.394, Cancer Detection and Extramural Policy and Review, National Diagnosis Research; 93.395, Cancer Institute on Drug Abuse, NIH, DHHS, 6001 Treatment Research; 93.396, Cancer Biology Executive Blvd., Room 4238, MSC 9550, DEPARTMENT OF HEALTH AND Research; 93.397, Cancer Centers Support; Bethesda, MD 20892–9550, 301–827–5819, HUMAN SERVICES 93.398, Cancer Research Manpower; 93.399, gm145a@nih.gov. Cancer Control, National Institutes of Health, Name of Committee: National Institute on National Institutes of Health HHS) Drug Abuse Special Emphasis Panel; Phase II: Avenir Award Program for Research on National Cancer Institute; Notice of Dated: February 13, 2018. sradovich on DSK3GMQ082PROD with NOTICES Substance Abuse and HIV/AIDS (DP2). Closed Meetings Melanie J. Pantoja, Date: March 19, 2018. Program Analyst, Office of Federal Advisory Time: 8:00 a.m. to 5:00 p.m. Pursuant to section 10(d) of the Federal Advisory Committee Act, as Committee Policy. Agenda: To review and evaluate grant applications. amended, notice is hereby given of the [FR Doc. 2018–03322 Filed 2–16–18; 8:45 am] Place: Courtyard by Marriott Chevy Chase, following meetings. BILLING CODE 4140–01–P 5520 Wisconsin Avenue, Chevy Chase, MD The meetings will be closed to the 20815. public in accordance with the VerDate Sep<11>2014 17:55 Feb 16, 2018 Jkt 244001 PO 00000 Frm 00066 Fmt 4703 Sfmt 9990 E:\FR\FM\20FEN1.SGM 20FEN1


Document Created: 2018-02-17 02:29:29
Document Modified: 2018-02-17 02:29:29
CategoryRegulatory Information
CollectionFederal Register
sudoc ClassAE 2.7:
GS 4.107:
AE 2.106:
PublisherOffice of the Federal Register, National Archives and Records Administration
SectionNotices
DatesMarch 7, 2018.
FR Citation83 FR 7200 
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR